Veracyte to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. William Blair 45th Annual Growth Stock Conference – Chicago, IL Presentation on June 3rd at 5:40 p.m. Eastern Time Jefferies Global Healthcare Conference – New York, NY Presentation on June 4th at 2:00 p.m. Eastern Time Live audio webcasts of the company's presentations will be available by visiting Veracyte'.
Veracyte Stock Surges 30.9% in a Year: What's Driving the Rally?
Strength in VCYT's Afirma and Decipher tests continues to draw investors' attention.
Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin Up
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests in the first quarter of 2025.
What Makes Veracyte (VCYT) a New Buy Stock
Veracyte (VCYT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Veracyte, Inc. (VCYT) Q1 2025 Earnings Call Transcript
Veracyte, Inc. (NASDAQ:VCYT ) Q1 2025 Earnings Call May 7, 2025 4:30 PM ET Company Participants Shayla Gorman - Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Officer John Leite - Chief Commercial Officer Conference Call Participants Subbu Nambi - Guggenheim Securities Andrew Brackmann - William Blair Puneet Souda - Leerink Partners Colleen Babington - Wolfe Research Tejas Savant - Morgan Stanley Thomas DeBourcy - Nephron Research Sung Ji Nam - Scotiabank Operator Good day and thank you for standing by. Welcome to the Veracyte First Quarter 2025 Financial Results Webcast.
Veracyte (VCYT) Q1 Earnings and Revenues Beat Estimates
Veracyte (VCYT) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to loss of $0.02 per share a year ago.
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer.
Should You Continue to Hold Veracyte Stock in Your Portfolio?
Strength in the Afirma and Decipher franchises continues to bode well for VCYT stock.
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Veracyte (VCYT) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Veracyte (VCYT) Just Overtook the 20-Day Moving Average
After reaching an important support level, Veracyte (VCYT) could be a good stock pick from a technical perspective. VCYT surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.
Strength Seen in Veracyte (VCYT): Can Its 13.0% Jump Turn into More Strength?
Veracyte (VCYT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
